ArticleBMC medical imaging2026
MRI findings of intrahepatic cholangiocarcinoma with sarcomatoid differentiation: a retrospective case series.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo describe MRI findings of intrahepatic cholangiocarcinoma with sarcomatoid differentiation (s-iCCA), summarize associated clinical features, and explore imaging characteristics that may help distinguish it from conventional intrahepatic cholangiocarcinoma. MATERIALS AND
methodsThis retrospective single-center study reviewed surgically resected, pathology-proven s-iCCA between June 2018 and September 2025. Patients who underwent preoperative liver magnetic resonance imaging (MRI) with dynamic contrast enhancement and diffusion-weighted imaging (DWI) were included; tumors arising from the extrahepatic bile duct or gallbladder and those treated before MRI were excluded. Two radiologists evaluated lesion morphology, signal characteristics, enhancement pattern, and tumor spread independently. Clinical, laboratory, pathologic, treatment, and follow-up data were collected.
resultsFive patients (2 men, 3 women; mean age, 64 years) were included. Serum carbohydrate antigen 19-9 (CA 19-9) was elevated in all patients, whereas alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA) were within reference range in tested patients. All tumors presented as a dominant mass-forming lesion (3.4-9.4 cm; segments V-VII (right), n = 4; segments III/IV (left), n = 1). On MRI, lesions were hypointense on T1-weighted imaging and heterogeneously hyperintense on T2-weighted imaging; intratumoral hemorrhage suggested by T1 hyperintensity was observed in two patients, and extensive nonenhancing necrosis/cystic degeneration in three. All tumors showed marked diffusion restriction on DWI. Dynamic imaging demonstrated arterial peripheral rim enhancement with progressive and persistent heterogeneous enhancement without washout in all cases. Segmental bile duct dilatation was present in two patients, suspected portal vein tumor thrombus in one, and regional lymphadenopathy in three. Extensive necrosis or cystic degeneration was common and contributed to marked imaging heterogeneity.
conclusionIn this small series, s-iCCA frequently appeared as a necrotic and heterogeneous mass-forming lesion with diffusion restriction and progressive enhancement. Although these findings substantially overlap with those of conventional iCCA, prominent necrosis and marked heterogeneity may raise suspicion for sarcomatoid differentiation in the appropriate clinical context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.